- SomaLogic was founded in 2000 by Larry Gold, who earlier founded NeXstar Pharmaceuticals, which was acquired by Gilead (GILD) for $550M.
- Institutional holders in the company include Ark Investment Management, Perceptive Advisors, Illumina, Softbank, Redmile Group, etc.
- The SomaScan Discovery Platform can analyze 7000 proteins in just 55 microL of blood sample, over 3.5x than competition.
- Current customers include Bristol-Myers Squibb (BMY), Novartis, Stanford, University of Cambridge, Henry Ford Health System, Alkahest, Louisiana State University, etc.
- This could be a 10x potential investment opportunity in a 10+ years time frame even if it occupies just 10% market share in the global proteomics market.
For further details see:
SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics